Allergen Immunotherapy for the Prevention and Treatment of Asthma DOI Creative Commons
Thierry Batard, Camille Taillé, Laurent Guilleminault

et al.

Clinical & Experimental Allergy, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 4, 2024

Allergic asthma is the predominant phenotype among asthmatics. Although conventional pharmacotherapy a central component in management of asthma, it does not enable control symptoms all patients. In recent decades, some uncontrolled asthmatic patients, especially those with allergic have benefited from biological therapies. However, biologics do address unmet needs left by pharmacotherapy. Furthermore, noteworthy that neither nor therapies disease-modifying properties. this context, allergen immunotherapy (AIT) represents an indispensable therapeutic arsenal against due to its immunological effects. review article, funded AIT manufacturer, we find clinical trials support as only treatment option able both improve and prevent onset worsening condition. For patients severe or other safety concerns, combination offers very promising new modalities for asthma. Trial Registration: clinicaltrials.gov identifier: NCT06027073.

Language: Английский

Update on pathomechanisms and treatments in allergic rhinitis DOI
Yuan Zhang, Feng Lan, Luo Zhang

et al.

Allergy, Journal Year: 2022, Volume and Issue: 77(11), P. 3309 - 3319

Published: July 27, 2022

Abstract Allergic rhinitis (AR) is a global health problem with increasing prevalence and association an enormous medical socioeconomic burden. New recognition of immune cells such as type 2 innate lymphocytes (ILC2s), T helper (Th2) cells, follicular regulatory B dendritic epithelial in AR pathogenesis has been updated this review paper. An in‐depth understanding the mechanisms underlying will aid identification biomarkers associated disease ultimately provide valuable parameters critical to guide personalized targeted therapy. As only etiological treatment option for AR, allergen‐specific immunotherapy (AIT) attracted attention, evidence effectiveness AIT recently demonstrated several randomized controlled trials long‐term real‐life studies. The exploration biologics therapeutic options involved anti‐IgE anti‐type inflammatory agents; however, cost‐effectiveness these agents remains be elucidated precisely. In midst currently on‐going COVID‐19 pandemic, life‐threatening disease, although some studies have indicated that not risk factor severity mortality COVID‐19, needs confirmed multi‐centre, patients from different parts world.

Language: Английский

Citations

94
Guideline on allergen immunotherapy in IgE-mediated allergic diseases DOI
Oliver Pfaar,

Tobias Ankermann,

Matthias Augustin

et al.

Allergologie select, Journal Year: 2022, Volume and Issue: 6(01), P. 167 - 232

Published: Jan. 1, 2022

Not available.

Language: Английский

Citations

83
Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation DOI Open Access
Ümit Murat Şahiner, Mattia Giovannini, María M. Escribese

et al.

Journal of Personalized Medicine, Journal Year: 2023, Volume and Issue: 13(5), P. 845 - 845

Published: May 17, 2023

Allergen-immunotherapy (AIT) is an efficacious and disease-modifying treatment option for IgE-mediated diseases. Among these allergic rhinitis, insect venom allergy, food asthma are the most common candidates AIT. AIT gives rise to clinical immunotolerance which may last years after cessation. Mechanisms of include suppression inflammation in target tissues stimulation production blocking antibodies, especially IgG4 IgA. These mechanisms followed by a reduction underlying allergen-specific Th2 cell-driven responses allergens. Tolerance induction takes place through desensitization effector cells regulatory T that show their effects involving cell-cell cross-talk, but also other mechanisms, e.g., immunomodulatory cytokines such as, IL-10 TGF-beta. From personalized medical perspective, there need biomarkers value selecting responders optimizing patient care during Also, deeper understanding mechanistic processes will improve AIT’s future outcomes. In this paper, current knowledge reviewed with special focus on therapy.

Language: Английский

Citations

29
Hot topics in allergen immunotherapy, 2023: Current status and future perspective DOI Creative Commons
Magdalena Zemelka‐Wiącek, Ioana Agache, Cezmi A. Akdiş

et al.

Allergy, Journal Year: 2023, Volume and Issue: 79(4), P. 823 - 842

Published: Nov. 20, 2023

The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality-of-life improvements cost-effectiveness in the long term. Key mechanisms tolerance induced by AIT include changes memory type allergen-specific T- B-cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression IgE increased IgG

Language: Английский

Citations

27
House dust mite SCIT reduces asthma risk and significantly improves long‐term rhinitis and asthma control—A RWE study DOI Creative Commons
Marek Jutel, Ludger Klimek, Hartmut Richter

et al.

Allergy, Journal Year: 2024, Volume and Issue: 79(4), P. 1042 - 1051

Published: March 2, 2024

Abstract Background The German Therapy Allergen Ordinance (TAO) triggered an ongoing upheaval in the market for house dust mite (HDM) allergen immunotherapy (AIT) products. Three HDM subcutaneous AIT (SCIT) products hold approval Germany and therefore will be available after scheduled completion of TAO procedure 2026. In general, data from clinical trials on long‐term effectiveness are rare. We evaluated real‐world (RWD) a retrospective, observational cohort study based longitudinal claims database including 60% all statutory healthcare prescriptions to show one these daily life. Aim this analysis was provide per product as it is demanded by international guidelines AIT. Methods Subjects between 5 70 years receiving their first (index) prescription SCIT with native (SCIT group) 2009 2013 were included. exactly 3:1 matched control group received only symptomatic AR medication (non‐AIT group); evaluation period up 6 follow‐up ended February 2017. Study endpoints progression allergic rhinitis (AR) asthma, asthma occurrence time onset at least 2 treatment years. Results total, 892 subjects (608 adults 284 children/adolescents) included 2676 (1824 852 non‐AIT group. During SCIT, number reduced 62.8% ( p < .0001) 42.4% = .0003). New‐onset risk significantly vs 27.0% .0212). asthma‐preventive effect occurred 15 months start treatment. group, prolonged compared .0010). Conclusion RWD product, patients aged benefited long term terms effects seemed last termination. A observed, starting

Language: Английский

Citations

10
Immune signatures predict response to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis DOI
Nan Wang, Jia Song,

Shi‐Ran Sun

et al.

Allergy, Journal Year: 2024, Volume and Issue: 79(5), P. 1230 - 1241

Published: Feb. 25, 2024

Identifying predictive biomarkers for allergen immunotherapy response is crucial enhancing clinical efficacy. This study aims to identify such in patients with allergic rhinitis (AR) undergoing subcutaneous (SCIT) house dust mite allergy.

Language: Английский

Citations

9
Genetically predicted N-methylhydroxyproline levels mediate the association between naive CD8+ T cells and allergic rhinitis: a mediation Mendelian randomization study DOI Creative Commons
Zhengjie Chen,

英男 別所,

Xintao Du

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: May 23, 2024

Background Allergic rhinitis (AR), a prevalent chronic inflammatory condition triggered by immunoglobulin E (IgE), involves pivotal roles of immune and metabolic factors in its onset progression. However, the intricacies uncertainties clinical research render current investigations into their interplay somewhat inadequate. Objective To elucidate causal relationships between cells, metabolites, AR, we conducted mediation Mendelian randomization (MR) analysis. Methods Leveraging comprehensive publicly accessible summary-level data from genome-wide association studies (GWAS), this study employed two-sample MR method to investigate among 731 cell phenotypes, 1400 metabolite levels, AR. Additionally, employing approach, analyzed potential mediated effect metabolites cells Various sensitivity analysis methods were systematically ensure robustness results. Results Following false discovery rate (FDR) correction, identified three phenotypes as protective for AR: Naive CD8br %CD8br (odds ratio (OR): 0.978, 95% CI = 0.966–0.990, P 4.5×10 –4 ), CD3 on CD39+ activated Treg (OR: 0.947, 0.923–0.972, 3×10 –5 HVEM CD45RA- CD4+ 0.967, 0.948–0.986, 4×10 ). levels risk N-methylhydroxyproline 1.219, 1.104–1.346, 9×10 N-acetylneuraminate 1.133, 1.061–1.211, 1.7×10 1-stearoyl-2-arachidonoyl-gpc (18:0/20:4) 1.058, 1.029–1.087, 5×10 Mediation indicated relationship acting factor 0.971, 0.950–0.992, 8.31×10 –3 The was -0.00574, accounting 26.1% total effect, with direct -0.01626. CD8+ T exert AR reducing levels. Conclusion Our study, delving genetic information, has substantiated intricate connection This reveals pathway prevent providing guiding directions future investigations.

Language: Английский

Citations

8
Helminth Therapy for Immune-Mediated Inflammatory Diseases: Current and Future Perspectives DOI Creative Commons
Wenjie Shi, Ning Xu, Xuelin Wang

et al.

Journal of Inflammation Research, Journal Year: 2022, Volume and Issue: Volume 15, P. 475 - 491

Published: Jan. 1, 2022

Abstract: Inflammatory bowel disease and allergic asthma, as typical immune-mediated inflammatory diseases (IMIDs), are associated with immune imbalance caused by complex interactions among environmental, genetic bacterial factors. The changing of IMIDs not only causes serious pathological damages but also increases the difficulty treatment. Helminths or helminth-derived molecules have been increasingly employed to treat due their immunoregulatory ability. Since helminth infection is an appropriate treatment direction immunoregulation safety concerns, one new therapies harness induced identified using indexes a guide. This review discusses pathogenesis summarizes therapeutic effect helminths mechanisms proposing regimens. Keywords: disease, immunoregulation, IMIDs, therapy,

Language: Английский

Citations

28
Allergen immunotherapy for allergic asthma DOI
J. Christian Virchow, Oliver Pfaar, Marek Lommatzsch

et al.

Allergologie select, Journal Year: 2024, Volume and Issue: 8(01), P. 6 - 11

Published: Jan. 1, 2024

Remission is the goal of modern asthma treatment. Allergen immunotherapy (AIT) an essential component in armamentarium personalized therapy. Subcutaneous AIT (SCIT) or sublingual (SLIT) offer possibility to prevent patients with allergic rhinitis (reduction risk developing asthma) and achieve remission asthma. Accordingly, should always be considered a documented, clinically relevant allergy. However, precise phenotyping patient prerequisite for success

Language: Английский

Citations

6
Managing the allergy and asthma epidemic in 2020s—Lessons from the Finnish experience DOI Creative Commons
Tari Haahtela, Juha Jantunen,

Kimmo Saarinen

et al.

Allergy, Journal Year: 2022, Volume and Issue: 77(8), P. 2367 - 2380

Published: Feb. 24, 2022

In Finland, a systematic public health programme was implemented from 2008 to 2018 mitigate the burden of allergic disorders by revisiting prevention strategy. Allergy and contacts with natural environment were emphasized promote immunological psychological resilience instead poorly justified avoidance. management practices improved low-valued recommendations for care, example food allergy, revised. Patients families empowered use guided self-management proactively stop symptom exacerbations. A professional non-governmental organization nationwide education healthcare patient NGOs patients, lay public. healthcare, work supporting patients organized towards common goals integrated into everyday without extra costs. Reaching predefined followed employing national registers questionnaire surveys. Governmental bodies contributed kick-off funding, which supplemented private funding. International collaboration, European (EFA), increased awareness Finnish action predisposed it peer review. The 10-year results are favourable, less disabled, attitudes in have changed, major cost savings been obtained. Views slow move, however. Local multidisciplinary allergy teams set up continue activities also after Programme. Changes lifestyle last 50 years main reasons rise. experience may help manage diseases, improve nature relatedness fast-urbanizing world, combat loss reduce disease burden.

Language: Английский

Citations

24